T. Rowe Price Investment Management Inc. increased its holdings in Acelyrin, Inc. (NASDAQ:SLRN - Free Report) by 23.4% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 12,872,124 shares of the company's stock after purchasing an additional 2,440,278 shares during the period. T. Rowe Price Investment Management Inc. owned approximately 12.83% of Acelyrin worth $40,419,000 at the end of the most recent quarter.
A number of other hedge funds also recently bought and sold shares of SLRN. Virtu Financial LLC purchased a new stake in shares of Acelyrin during the 3rd quarter valued at about $50,000. XTX Topco Ltd purchased a new stake in Acelyrin during the fourth quarter valued at approximately $33,000. Hsbc Holdings PLC bought a new stake in shares of Acelyrin in the 4th quarter valued at approximately $36,000. RPO LLC purchased a new position in shares of Acelyrin in the 4th quarter worth approximately $46,000. Finally, Intech Investment Management LLC raised its holdings in Acelyrin by 71.0% during the 4th quarter. Intech Investment Management LLC now owns 26,587 shares of the company's stock valued at $83,000 after buying an additional 11,040 shares during the period. Hedge funds and other institutional investors own 87.31% of the company's stock.
Analysts Set New Price Targets
Several brokerages have recently weighed in on SLRN. Citigroup reduced their target price on shares of Acelyrin from $6.00 to $3.00 and set a "neutral" rating on the stock in a research note on Tuesday, January 7th. HC Wainwright dropped their target price on Acelyrin from $8.00 to $6.00 and set a "neutral" rating for the company in a research report on Tuesday, January 7th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $9.60.
View Our Latest Stock Analysis on SLRN
Insider Activity
In related news, CEO Mina Kim sold 17,986 shares of the firm's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $2.74, for a total transaction of $49,281.64. Following the sale, the chief executive officer now owns 671,753 shares of the company's stock, valued at $1,840,603.22. This trade represents a 2.61 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 13.60% of the company's stock.
Acelyrin Stock Performance
Shares of SLRN stock opened at $2.17 on Friday. Acelyrin, Inc. has a twelve month low of $1.85 and a twelve month high of $7.25. The stock has a fifty day simple moving average of $2.47 and a two-hundred day simple moving average of $3.36. The stock has a market capitalization of $218.97 million, a price-to-earnings ratio of -0.88 and a beta of 1.12.
Acelyrin (NASDAQ:SLRN - Get Free Report) last released its quarterly earnings data on Wednesday, March 19th. The company reported ($0.79) earnings per share for the quarter, topping analysts' consensus estimates of ($0.86) by $0.07. Research analysts predict that Acelyrin, Inc. will post -2.53 EPS for the current fiscal year.
Acelyrin Profile
(
Free Report)
Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Acelyrin, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Acelyrin wasn't on the list.
While Acelyrin currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
